NR-19271甲型流感病毒,H1N1pdm09Gateway?克隆集,在大肠杆菌中重组(克隆）
产品图片
货号/SKU
NR-19271
货号/规格
EA
库存与交货期
3-8周
人民币价格
14000
试剂海关审批
A/B级风险物质只能直接使用人购买并持有实验室有效资质，其它询客服确认
国外采购
支持/部分限制一年内购买数量
厂牌
BEI Resources(ATCC)
产品基础信息
生物安全等级建议分类：美国、1
产品描述信息
NR-19271??Influenza A virus, H1N1pdm09 Gateway? Clone Set, Recombinant in Escherichia coli(Clones)|Influenza A virus|H1N1pdm09 Gateway? Clone Set, Recombinant in Escherichia coli|-80°C or colder|Pathogen Functional Genomics Resource Center at the J. Craig Venter InstituteAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: H1N1pdm09 Gateway? Clone Set, Recombinant in Escherichia coli, NR-19271."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
The H1N1pdm09 Gateway? Clone Set contains Influenza A (H1N1)pdm09 open reading frames from two clinical isolates A/New York/1682/2009 (H1N1)pdm09 (CY039901 to CY039908) and A/New York/1669/2009 (H1N1)pdm09 (CY039893 to CY039900) cloned in Escherichia coli (E. coli) DH10B or Stbl4 cells. The clone set consists of twenty-seven clones that were constructed in vector pDONR?221. The full annotated coding sequence (CDS) for each genomic segment has been cloned (stop codons removed) and the sequence verified. The transmembrane regions of the hemagglutinin and neuraminidase coding sequences have been truncated.
Information related to the use of Gateway? Clones can be obtained from Invitrogen?. Recombination was facilitated through an attB substrate (attB-PCR product or a linearized attB expression clone) with an attP substrate (pDONR?221) to create an attL-containing entry clone. The entry clone contains recombinational cloning sites, attL1 and attL2 to facilitate gene transfer into a destination vector, M13 forward and reverse priming sites for sequencing and a kanamycin resistance gene for selection. Please refer to the Invitrogen? Gateway? Technology Manual for additional details.
Each well of the 96-well plate contains approximately 50 ?L of E. coli culture (strain DH10B-T1 or strain Stbl4) in Luria Bertani (LB) broth containing 50 ?g/mL kanamycin supplemented with 15% glycerol.
Plate orientation and viability were confirmed for NR-19271.
Clone plates are replicated using a BioMek? FX robot. Production in the 96-well format has increased risk of cross-contamination between adjacent wells. Individual clones should be purified (e.g. single colony isolation and purification using good microbiological practices) and sequence-verified prior to use. BEI Resources only confirms the clone plate orientation and viability of randomly picked clones. BEI Resources does not confirm or validate individual clone identities provided by the contributor.
The H1N1pdm09 Gateway? Clone Set contains Influenza A (H1N1)pdm09 open reading frames from two clinical isolates A/New York/1682/2009 (H1N1)pdm09 (CY039901 to CY039908) and A/New York/1669/2009 (H1N1)pdm09 (CY039893 to CY039900) cloned in Escherichia coli (E. coli) DH10B or Stbl4 cells. The clone set consists of twenty-seven clones that were constructed in vector pDONR?221. The full annotated coding sequence (CDS) for each genomic segment has been cloned (stop codons removed) and the sequence verified. The transmembrane regions of the hemagglutinin and neuraminidase coding sequences have been truncated.
Information related to the use of Gateway? Clones can be obtained from Invitrogen?. Recombination was facilitated through an attB substrate (attB-PCR product or a linearized attB expression clone) with an attP substrate (pDONR?221) to create an attL-containing entry clone. The entry clone contains recombinational cloning sites, attL1 and attL2 to facilitate gene transfer into a destination vector, M13 forward and reverse priming sites for sequencing and a kanamycin resistance gene for selection. Please refer to the Invitrogen? Gateway? Technology Manual for additional details.
Each well of the 96-well plate contains approximately 50 ?L of E. coli culture (strain DH10B-T1 or strain Stbl4) in Luria Bertani (LB) broth containing 50 ?g/mL kanamycin supplemented with 15% glycerol.
Plate orientation and viability were confirmed for NR-19271.
Clone plates are replicated using a BioMek? FX robot. Production in the 96-well format has increased risk of cross-contamination between adjacent wells. Individual clones should be purified (e.g. single colony isolation and purification using good microbiological practices) and sequence-verified prior to use. BEI Resources only confirms the clone plate orientation and viability of randomly picked clones. BEI Resources does not confirm or validate individual clone identities provided by the contributor.
主要内容
此项目的每个订单数量限制为1.此商品每年可订购两次.通过此限制的订单将在发货前发送到NIAID进行批准. H1N1PDM09网关?克隆组包含来自两个临床的流感A（H1N1）PDM09开放阅读框架分离A / New York / 1682/2009（H1N1）PDM09（ cy039901至cy039908 ）和A / New York / 1669/2009（H1N1）PDM09（ cy039893至cy039900 ）克隆在大肠杆菌（大肠杆菌）中克隆i> DH10B或STBL4细胞.克隆集由二十七个克隆组成，该克隆是在传染媒介 pdonr?221 .已经克隆了每个基因组片段的完全注释的编码序列（CDS）（移除了止核密码子）并验证序列.血凝素和神经氨酸酶编码序列的跨膜区域已被截断. 与使用网关?克隆有关的信息可以从 Invitrogen ?.通过 att b底板（ att b-pCR产物或线性化的 att b表达克隆）促进重组，用 att P衬底（PDONR?221）以产生含有含有ATT L的入口克隆.进入克隆含有重组克隆位点， att l1和 att L2，以促进基因转移到目的载体中，用于测序和卡那霉素抗性基因的目的载体，M13向前和逆向引发位点选择.请参阅Invitrogen?网关?技术手册更多详情. 96孔板的每个孔含有约50μl的 e. Coli 培养（菌株DH10B-T1或菌株STBL4）在含有50μg/ mL卡那霉素的LURIA Bertani（LB）肉汤中，所述甘油补充有15％甘油. NR-19271确认了板式方向和活力. 克隆板使用生物孔? fx机器人复制. 96孔格式的生产增加了相邻井之间的交叉污染风险.应纯化各个克隆（例如，使用良好的微生物实践的单菌落分离和纯化）并在使用前进行序列验证. Bei Resources仅确认随机挑选的克隆的克隆板取向和可存度. Bei资源不确认或验证贡献者提供的单个克隆身份.
厂牌介绍
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立，旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中，可以监控科学界对这些材料的访问和使用，并确保试剂的质量控制。
除了为传染病界提供材料外，BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势，包括安全存储、社区访问和分发；同时保护存款人的知识产权。只要有需要，BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月， ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料，包括由其他政府支持的研究项目存放的材料，将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中，涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
品牌标识
可能感兴趣的内容
2023-07-18
2019-06-24
2024-08-16
2022-04-01
2024-08-16
2021-12-21
2024-03-25
2021-12-21
2022-03-22
2022-04-01
2021-12-21
2021-12-21
2022-04-01
2024-01-21
2021-12-21
2021-12-21